The $215 Billion Tollbooth: Anatomy of an Engineered Bottleneck

We tolerate a financial structure in healthcare that would get a procurement manager fired in any other industry.Out of the $650 billion spent annually on drugs in the U.S., roughly $215 billion is captured by intermediaries. The system is not broken; it is functioning exactly as its contracts dictate. -----------------Pharmacy Benefit Managers (PBMs) are compensated based on a percentage of drug list prices. They are financially incentivised to ignore cheap generics and push expensive, high-rebate drugs.-----------------In this episode, we break down the mechanics of the gross-to-net pricing bubble. We bypass the standard industry outrage to look directly at the math, the measurement blind spots, and the waste flow.-----------------Inside the Episode:Why your cost-containment dashboards are showing record savings while your actual spending goes up.The mechanics of how percentage-based rebates block biosimilar adoption.How to execute a one-week, zero-capex formulary audit on your top 20 drugs.The financial impact of moving to a flat administrative fee (projected to compress spend by up to 15%).-----------------If you are a finance or operations leader relying on aggregate rebate reporting, you are measuring the size of your blind spot. Listen in to learn how to measure the baseline.-----------------Stay Tuned…Regards, Top VoiceMaido & Kon'nichiwa min'na! 👶🏻🧑🏻‍🦱👩🏻‍🦳Wie Geht's guys? Mir geht's gut!!! ✌️🤘🙌#SupplyChain #OperationalExcellence #FinOps #HealthcareFinance #SystemDesign #ProcessEngineering #OperationsManagement #IndustrialEngineering #SystemsThinking #SupplyChainManagement #CostControl